The corporate-backed health management service raised the cash from Perceptive Advisors and has used $30m to buy musculoskeletal-focused Physera.
Life sciences investment firm Perceptive Advisors has provided an amount reported by CNBC to be $57m in funding for Omada Health, a US-headquartered illness management platform developer backed by several corporates.
Omada has used $30m of the cash to fund the acquisition of Physera, the US-based creator of a musculoskeletal injury management app that had raised $10.8m in funding from investors including health insurance association Blue Cross Blue Shield.
Founded in 2011, Omada provides an app-based service that helps users manage health conditions including diabetes, hypertension and now musculoskeletal issues in addition to behavioural health.
The company had secured about $200m in funding altogether, prior to an investment of undisclosed size by Intermountain Ventures, the corporate venture capital arm of healthcare provider Intermountain Healthcare, in October 2019.
Omada received $73m four months earlier, in a round featuring pharmaceutical firm Sanofi and care providers Kaiser Permanente, Cigna and Providence…
